EDS / hypermobility (hEDS, HSD)
Ehlers-Danlos syndromes and hypermobility spectrum disorders — heritable connective-tissue disorders with joint instability, chronic pain, skin/tissue fragility, and frequent autonomic + mast-cell overlap.
What changes during this transition
EDS is a group of 13 heritable connective-tissue disorders. The most common subtype, hypermobile EDS (hEDS), still has no confirmed genetic marker — diagnosis follows the 2017 Villefranche/Malfait clinical criteria + Beighton score. Hypermobility spectrum disorders (HSD) cover symptomatic hypermobility not meeting hEDS criteria. Other subtypes have confirmed genetic markers — classical EDS (COL5A1/COL5A2), vascular EDS (COL3A1, life-threatening), kyphoscoliotic (PLOD1), dermatosparaxis (ADAMTS2), arthrochalasia (COL1A1/COL1A2). hEDS is the third pillar of the well-documented EDS-MCAS-POTS triad, with ~30-50% co-prevalence in tertiary centers. Standard-of-care is PT-focused STABILIZATION (NOT stretching), multimodal pain management (low-dose tricyclics, duloxetine, topical lidocaine, nerve blocks; opioids generally avoided), sleep hygiene + ergonomic supports, cardiology screening for aortic root and mitral valve, and genetics referral when vascular or classical features are present. Peptides relevant here cluster around the triad-overlap pillars: KPV for the MCAS pillar, B12-methylcobalamin for the small-fiber neuropathy that Cazzato 2016 documented in 100% of a hEDS cohort, and GHK-Cu for the copper-lysyl-oxidase-collagen-cross-linking rationale (theoretically appealing, evidence-thin in EDS specifically). BPC-157 and TB-500 carry heavy community use for joint laxity claims but raise a load-bearing vEDS-exclusion concern (angiogenic mechanisms in collagen-defective vasculature) and are substrate-only.
Important caveat
SUBTYPE IDENTIFICATION FIRST. If your subtype hasn't been confirmed via genetic testing or clinical Villefranche/Malfait 2017 assessment — or if family history includes unexplained arterial dissection, organ rupture, or sudden death in a young relative — genetics referral comes BEFORE any peptide decision. Vascular EDS (vEDS, COL3A1) is life-threatening. Angiogenic peptides (BPC-157, TB-500) in collagen-defective vasculature are mechanism-aligned with the WRONG DIRECTION — substrate-only, not surfaced here.
Peptides editorially relevant to eds / hypermobility (heds, hsd)
3 peptides from the library — each evidence-tiered honestly.
- KPVTier 3
α-MSH C-terminal tripeptide
Short tripeptide fragment of a natural hormone (alpha-MSH). Appears to carry the anti-inflammatory signaling of the parent hormone without its pigmentation effects. Growing animal and early-human work, especially for inflammatory bowel disease.
- B12 (Methylcobalamin)Tier 1
Vitamin (methylcobalamin)
Vitamin B12 in the methyl form. Solid evidence for treating documented deficiency and pernicious anemia. The wellness-clinic 'energy injection' market for non-deficient adults has no clinical-trial support.
- GHK-CuTier 2
Copper tripeptide
Strong topical evidence in skin and wound healing. Injectable systemic claims are an entirely different evidence base and tier.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.